Patient satisfaction at 24 months after treatment for localized prostate cancer

The ability to “manage” patients’ satisfaction with their care in the treatment of localized prostate cancer is challenging — for patients, for caregivers, for physicians, and for health systems. … READ MORE …

Patient choice and the effectiveness and safety of HIFU

An interesting article has just been published in the Journal of Urology which helps to provide information (and context) about the quality of data supporting the use of high-intensity focused ultrasound (HIFU) in the treatment of prostate cancer. … READ MORE …

Why is this debate still going on at all?

The question between different types of physician as to whether radiation therapy or surgery is “better” for the first-line, curative treatment of localized prostate cancer has now been debated (over and over) for more than 40 years. … READ MORE …

Patient preference and type of chemotherapy for mCRPC

In another presentation from the ESMO meeting in  Madrid, Spain, Fizazi et al. presented data from the randomized CABA-DOC trial  exploring patients’ preferences for either docetaxel or cabazitaxel as a first-line form of chemotherapy. … READ MORE …

Decision making and the treatment of localized prostate cancer today

This month’s issue of Urologic Oncology contains a series of six articles that may be of particular interest to prostate cancer support group leaders and other prostate cancer educators. … READ MORE …

Systematic counseling and rates of acceptance of active surveillance

According to a newly published paper in European Urology, a simple, hour-long lecture and training session can improve the ability of physicians to counsel patients systematically about active sureveillance and, at one major center, improved patient acceptance of active surveillance by as much as 17 percent. … READ MORE …

The impact of emotional distress on prostate cancer decision-making

According to a newly published paper in the Journal of Urology,

Emotional distress may motivate men with low risk prostate cancer to choose more aggressive treatment. Addressing emotional distress before and during treatment decision making may reduce a barrier to the uptake of active surveillance.

… READ MORE

Another Sunnybrook update: risk for metastasis on active surveillance

The Sunnybrook Group from the University of Toronto in Canada have just provided us with yet another update on the outcomes of their cohort of 980 patients managed initially on active surveillance and dating back to 1996. … READ MORE …

“Therapeutic illusion” and prostate cancer care

In this week’s New England Journal of Medicine there is what your sitemaster considers to be a highly informative article on what is known as “therapeutic illusion” and its impact on clinical practice. … READ MORE …

Can a new logistical approach radically change surgical options for patients?

One of the things we have been asked multiple times over the years is “What does it cost to have” a radical prostatectomy, or a penile implant, or some other prostate cancer-related procedure. Usually, we have had some idea, but it can be near to impossible to get precise, total costs for such procedures — even from your local hospital. … READ MORE …

To screen or not to screen: an Australian “discrete choice experiment”

The question of whether men should be regularly screened for risk of prostate cancer through the use of the PSA test is (at least) controversial … READ MORE …

Decision aids and patient choice of therapy: a randomized, controlled, clinical trial

A new paper in BJU International reports data about the development of an appropriate decision aid and the results of a randomized, controlled, clinical trial designed to investigate the effects of use of that decision aid (as opposed to “usual care”) on patients’ selection of radiation therapy as opposed to radical prostatectomy for localized disease. … READ MORE …

How young men have thought about treatment options for Gleason 6 prostate cancer

A new study based on data from nearly 500 patients gives us some insight into how a selected group of men less than 50 years of age were thinking about treatment for prostate cancer between 2001 and 2005. Whether one would get the same results for a similar group of patient diagnosed today is a good question. … READ MORE …

Use of CAM among rural prostate cancer patients in one US state

There is significant use of a variety of forms of complementary and alternative forms of medicine (CAM) among patients with localized prostate cancer. A new study in the Journal of Community Health has explored the prevalence and predictors of such behavior in a rural community setting. … READ MORE …

Why men choose specific first-line types of management for localized prostate cancer

The need for patients diagnosed with early stage prostate cancer to be highly involved in the decision as to which form of management they wish to be given is well understood. However, there has been a relative dearth of data on why patients actually make their individual decisions. … READ MORE …